EFMC Yearbook 2019

 

Embed or link this publication

Description

EFMC Yearbook 2019

Popular Pages


p. 1



[close]

p. 2



[close]

p. 3



[close]

p. 4



[close]

p. 5

Editorial 1 EFMC YEARBOOK 20179 Dear colleagues, In last year’s editorial, I was writing about the privilege of becoming president of the EFMC, thanking you for the opportunity and for your support. I feel the same sense of appreciation one year later, and particularly enjoy the fact that working together, we could help EFMC achieve exciting results. As you will read below, a lot happened in 2018. New initiatives and betterestablished projects all showed clear progress, while EFMC was very successful in organising high-quality scientific events. It is exciting to see the dynamism of our community. Besides offering a rich scientific program, 2019 will be a year of consolidation for EFMC. A workshop will take place in February to review EFMC’s activities and its strategic initiatives. The aim will not be to come up with completely new directions, but rather to reinforce ongoing efforts and ensure their success. In particular, we want to further support the integration of chemical biology and improve communication, extend activities for young scientists, as well as review our portfolio of scientific events, and work on best practices and on our internal processes. We will also strive to reinforce EFMC’s interactions with our partners across the world, while interacting closely with our national member organizations. Before providing an overview of the most important events of 2018 and of the activities planned by our Federation in 2019, I would sincerely like to thank Janos Sapi (France) and Trond Ulven (Denmark) for their years-long contribution to the EFMC Council. Their successors are Dominique Lesuisse (France) and Rasmus Praetorius Clausen (Denmark), to whom I extend a warm welcome. I would also like to thank the Executive Committee (EC) members for their constant support and valuable advice. Special thanks go to Pascal George, who accepted the position of treasurer five years ago, and who managed the EFMC finances through two consecutive terms. We are now looking forward to working with his successor, Antoni Torrens, who already has a solid experience within the EC. I also welcome Luc Van Hijfte as new EC Member, looking forward to a close collaboration. The other members of the EC are Koen Augustyns (Past President), Anders Karlén (Secretary), Rui Moreira, Matt Tozer and Henk Timmerman as EFMC Advisor. Finally, I would like to welcome our three new Corporate Members. AstraZeneca, Idorsia and Sanofi joined the group of companies who financially support the EFMC, its mission to advance the science of medicinal chemistry and chemical biology, as well as activities for young scientists. EFMC greatly appreciates their commitment. A review of 2018 Our main event last year was the XXV EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC 2018) which took place in Ljubljana (Slovenia) on September 2-6, 2018. Organised by the Section for Medicinal Chemistry of the Slovenian Pharmaceutical Society (SFD) on behalf of EFMC, it gathered around 1000 scientists from over 40 different nations. Over the years, the EFMC flagship event remains the key European symposium in medicinal chemistry and chemical biology. The excellent programme gathered by the International Organising Committee led by Marko Anderluh was particularly impressive. I would like to renew my thanks to all those who contributed to the success of this event.

[close]

p. 6

2 Editorial The EFMC Young Medicinal Chemist Symposium (EFMC-YMCS’18) immediately followed the ISMC meeting. It was exciting to see the ever-increasing number of young scientists taking part in this lively meeting, with excellent science and networking opportunities. I am grateful to Tihomir Tomasic and his committee for having put together an interesting program and for creating the right conditions for this dynamic exchange, which participants clearly appreciated. The 14th EFMC Short Course took place in April 2018 and was entitled “Peptide Therapeutics: Inspiring Beacon of Hope for the Pharmaceutical Future”. I am thankful to Bart De Spiegeleer and Henk Timmermann for organizing this course and contributing to EFMC’s training and networking objectives. This series will continue with a course on Fragment-based Drug Discovery, scheduled for April 28-May 1, 2019 and organised by Iwan De Esch (VU Amsterdam). The EFMC working groups provide valuable contributions in diverse areas, with the appreciated help from many participants. I invite you to have a closer look at the report on their activities on pages 10 to 13 of this Yearbook. EFMC collaborates with several federations within and beyond Europe to increase the international visibility of European medicinal chemistry and chemical biology. The policy workshop organised at the European parliament by Anders Kárlen, in partnership with EuChemS, is particularly worth mentioning. Focusing on Parkinson’s disease: Causes and Cures, it gave EFMC the opportunity to highlight the role of medicinal chemistry in discovering new therapies, as well as to discuss the scientific opportunities and funding needs for research in this area. EFMC also had numerous scientific interactions with partners around the world: Rui Moreira organised a session on “Boron in Medicinal Chemistry and Chemical Biology” at the 255th ACS National Meeting, and I had the pleasure to organise one on the “Medicinal Chemistry and Chemical Biology Continuum” at ICBS 2018. Our other partners (EuChemS; ACSMEDI; CPA; AFMC & EANM) contributed sessions at the EFMC-ISMC 2018. Each event was an opportunity for closer interactions and for reinforcing our collaborations. Finally, EFMC further implemented the decision to better integrate chemical biology. I am proud to announce that we have recently signed an agreement of mutual support with the International Chemical Biology Society (ICBS), and that we are collaborating with the Life Science division of the European Chemical Society (LS-EuChemS), including in the preparation of the European Chemical Biology Symposium (ECBS). Both organisations are important partners in the chemical biology landscape, and allow EFMC to extend its support of the European chemical biology and medicinal chemistry community. Eyes on the future Several EFMC events will take place in 2019: The EFMC-ACSMEDI MedChem Frontiers 2019 on June 10-13 in Krakow, Poland; the EFMC International Symposium on Advances in Synthetic and Medicinal Chemistry (EFMC-ASMC’19) on September 1-5, 2019 in Athens, Greece and the EFMC-Young Medicinal Chemist Symposium (EFMC-YMCS 2019) on September 5-6, also in Athens. I hope to see many of you at these events.

[close]

p. 7

EFMC YEARBOOK 2019 Editorial 3 To recognise scientific excellence, EFMC will once again confer the EFMC Prizes for Young Medicinal Chemists in Academia and Industry, to acknowledge the scientific accomplishments of two rising stars. The call for the 2019 prizes is open. There are many excellent scientists across Europe, and I encourage everyone to submit nominations before the deadline of January 31st. We believe that a young generation of medicinal chemists and chemical biologists will play an important role in addressing the current challenges of our discipline. To facilitate their integration in the community at an early stage of their career, we launched several initiatives around the EFMC Young Medicinal Chemists Symposium. They aim to facilitate networking, communication and presentation skills. The newly created “Young Scientists Network” (www.efmc.info/ysn) has the ambition to become a key tool for young scientists, providing them with specific information on events and trainings, awarding prizes to talented students, relaying job offers and PhD positions, and providing them with a forum to exchange, seek advice and mentoring. We will continue provide updates on EFMC activities through our monthly newsletter MedChemWatch, via the EFMC LinkedIn group, our Twitter, Facebook and Instagram accounts (talk to us as @euromedchem). Our website www.efmc.info has being redesigned for increased interactivity, and is always updated with the latest information, including a meeting calendar and a job portal. Furthermore, I encourage you to submit contributions to MedChemComm, the EFMC journal, published monthly in collaboration with RSC. Let me close by wishing you all the best for a successful and happy 2019, both in your professional and personal life. With my best personal regards, Yves P. Auberson EFMC President EFMC Administrative Secretariat LD Organisation sprl - Scientific Conference Producers Rue Michel de Ghelderode 33/2 - 1348 Louvain-la-Neuve, Belgium Tel: +32 10 45 47 74 Fax: +32 10 45 97 19 administration@efmc.info www.efmc.info

[close]

p. 8



[close]

p. 9

Table of Contents EFMC Presentation Editorial Table of Contents Sponsors Corporate Members Award Sponsors Executive Committee Council Advisory Board WG Groups MedChemWatch - Website - Social Media Report EFMC-ISMC 2018 EFMC Photo Contest 2018 EFMC Awards EFMC Prizes Report EFMC-YMCS 2018 Calendar of Events EFMC Short Course Report EFMC Short Course National Adhering Organisations Directory of Companies Austria Belgium Croatia Czech Republic Denmark Finland France Germany Greece Hungary Israel Italy Latvia The Netherlands Poland Portugal Russia Serbia Slovenia Spain Sweden Switzerland Turkey United Kingdom Directory of Companies 1 5 6 6 6 7 8 9 10 14 17 20 22 24 27 28 36 37 41 42 44 45 46 47 48 49 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 70 Medicinal Chemistry in Europe, the Yearbook of the European Federation for Medicinal Chemistry is published by: LD Organisation sprl Scientific Conference Producers Rue Michel de Ghelderode 33/2 - BE-1348 Louvain-la-Neuve, Belgium Tel: +32 10 45 47 77 - Fax: +32 10 45 97 19 administration@efmc.info Reproduction: All items published in this directory are protected by copyright. Reproduction by reprint, photocopy, microfilm or any other process is not allowed without the prior written permission of the publisher. www.efmc.info EFMC YEARBOOK 2019 5

[close]

p. 10

Sponsors 6 CProermpiourmateSpSopnosnosrors CHEMBRIDGE CORPORATION Premium Sponsors are CROs, Service Providers, Publishers that directly sponsor EFMC activities through major financial contributions. Their contribution helps the EFMC towards its main objective of developing a strong Medicinal Chemistry community in Europe that is well-equipped for the challenges of the future and enables the discovery of innovative new medicines for patients. Corporate Members EFMC offers any company the opportunity to become an official Corporate Sponsor. Corporate membership will help the EFMC with its objective of advancing the science of medicinal chemistry and can be achieved in paying an annual fee of €2000 to EFMC, or sponsoring one of its events with a contribution of 10.000€. Companies interested to become a Corporate Member should contact the Administrative Secretariat at administration@efmc.info ASTRAZENECA JANSSEN R&D F.HOFFMANN-LA ROCHE BAYER MERCK SANOFI BOEHRINGER INGELHEIM IDORSIA NOVARTIS PFIZER SERVIER UCB Award Sponsors EFMC is thankful to the below organisations to help in its mission to advance the science of Medicinal Chemistry and Chemical Biology in acknowledging and supporting excellence in the fields. The EFMC Awards are distributed biennially at the occasion of EFMC’s flagship meeting, the EFMC International Symposium on Medicinal Chemistry. NAUTA FOUNDATION PROUS INSTITUTE UCB

[close]

p. 11

EC Executive Committee 7 EFMC YEARBOOK 2019 The Executive Committee (EC) consists of seven members: the President, the President Elect or the Past President, the Secretary, the Treasurer and three additional members. All members of the EC, except the President and the Past President, are elected by secret ballot by the Council during a meeting of the Council. After a term of one year, the President Elect will automatically become President. The members of the EC are not delegates of their respective countries. All details about the election process can be found in the statutes of the EFMC on the EFMC official website: www.efmc.info President Past President Secretary Treasurer Member Member Member Activities Dr Yves P. AUBERSON Novartis Global Discovery Chemistry, WKL-136.6.82 Klybeckstrasse 141 - Basel, Switzerland Tel: +41-795939101 Email: yves.auberson@novartis.com Prof. Dr Koen AUGUSTYNS University of Antwerp Medicinal Chemistry Campus Drie Eiken - Building A, Room 2.07 Universiteitsplein 1 - 2610 Antwerpen, Belgium Tel: +32-3-265-27-17 - Fax: +32-3-265-27-39 Email: Koen.Augustyns@uantwerpen.be Prof. Dr Anders KARLÉN Uppsala University Department of Medicinal Chemistry BMC Box 574 – Uppsala, Sweden Tel : +46-701679177 – Fax: +46-184714474 Email : anders.karlen@orgfarm.uu.se Dr Antoni TORRENS Esteve Pharmaceuticals R&D Center Parc Científic de Barcelona, Baldiri i Reixach 4, Barcelona, Spain Tel : +34-934466000 Email : atorrens@esteve.es Prof. Dr Rui MOREIRA University of Lisbon – Faculty of Pharmacy Av. Prof. Gama Pinto - 1649-019 Lisbon, Portugal Tel : +351-217946477 – Fax : +351-217946470 Email : rmoreira@ff.ul.pt Dr Luc Van Hijfte Mercachem-Syncom Kerkenbos 1013, 6546 BB – Nijmegen, The Netherlands Tel : +32-242050316 Email : luc.vanhijfte@mercachem.com Dr Matthew TOZER Consultant Cambridge, United Kingdom Email : matttozer@hotmail.com The current affairs of the Federation are handled by the EC. Among its members, the EC will assign the responsibilities of International Liaison, Communication and Planning.

[close]

p. 12

Council 8 Council The Council consists of the members of the EC and one delegate of each Adhering Organisation. According to the statutes, the voting rights are allotted according to the following rules: members of the EC: 1 vote, countries with up to 99 members: 2 votes, countries with 100-199 members: 3 votes, countries with 200-399 members: 4 votes, countries with 400-599 members: 5 votes, countries with 600-899 members: 6 votes, countries with more than 899 members: 7 votes. As for countries with more than one Adhering Organisation, votes will be proportionally distributed among them, taking into a resulting number will be rounded off to the closest digit. Dr David ALKER David Alker Associates - The Biological and Medicinal Chemistry Sector (BMCS) of the Royal Society of Chemistry (RSC), United Kingdom Dr Yves P. AUBERSON Novartis, Switzerland - EFMC Executive Committee Prof. Dr Koen AUGUSTYNS University of Antwerp, Belgium - EFMC Executive Committee Prof. Dr Sergey BACHURIN Institute of Physiologically Active Compounds - The D.I. Mendeleev Russian Chemical Society, Medicinal Chemistry Section, Russia Prof. Dr Ayla BALKAN Hacettepe University - Turkish Association of Medicinal and Pharmaceutical Chemistry, Turkey Prof. Dr Rasmus Prætorius CLAUSEN University of Copenhagen - The Danish Society for Medicinal Chemistry and Chemical Biology, Denmark Prof. Dr Bernd CLEMENT Kiel University - German Pharmaceutical Society, Section of Pharmaceutical/Medicinal Chemistry (DPhG), Germany Prof. Dr Gabriele COSTANTINO Università degli Studi di Parma Division of Medicinal Chemistry of the Italian Chemical Society, Italy Prof. Dr Beatriz DE PASCUAL TERESA Universidad San Pablo Ceu - Sociedad Española de Química Terapéutica, Spain Prof. Dr Martin DOLEZAL Charles University - Section of Synthetic Drug of the Czech Pharmaceutical Society, Czech Republic Prof. Dr Gunars DUBURS Latvian Institute of Organic Synthesis - Latvian Association for Medicinal Chemistry, Latvia Dr Vesna GABELICA MARKOVIC Croatian Chemical Society, Medicinal Chemistry Section, Croatia Dr Georg JAESCHKE F. Hoffmann-La Roche - Division for Medicinal Chemistry & Chemical Biology (DMCCB), Switzerland Dr Annika JENMALM JENSEN Karolinska Institutet - Swedish Academy of Pharmaceutical Sciences, Sweden Prof. Dr Anders KARLÉN Uppsala University, Sweden - EFMC Executive Committee Prof. Dr György Miklós KESERU Hungarian Academy of Sciences - Organic and Medicinal Chemistry Division (OMCD) of the Hungarian Chemical Society (HCS), Hungary Prof. Dr Katarzyna KIEC-KONONOWICZ Jagiellonian University - Polish Society of Medicinal Chemistry, Poland Prof. Dr Danijel KIKELJ University of Ljubljana - Section for Medicinal Chemistry of the Slovenian Pharmaceutical Society, Slovenia Prof. Dr Thierry LANGER University of Vienna - Austrian Chemical Society, Medicinal Chemistry Section, Austria Dr Brigitte LESUR Institute de Recherches Servier - Société de Chimie Thérapeutique, France Dr Matilde MARQUES University of Lisbon - Division of Medicinal Chemistry of the Portuguese Chemical Society, Portugal Prof. Dr Emmanuel MIKROS University of Athens - Hellenic Society of Medicinal Chemistry, Greece Dr Peter MOLENVELD Mercachem-Syncom - Section Medicinal Chemistry, Royal Netherlands Chemical Society (KNCV), The Netherlands Prof. Dr Rui MOREIRA University of Lisbon, Portugal - EFMC Executive Committee Prof. Dr Igor OPSENICA University of Belgrade - Division of Medicinal Chemistry of the Serbian Chemical Society, Serbia Dr Laurent PROVINS UCB, Société Royale de Chimie (SRC) - Medicinal Chemistry Division, Belgium Prof. Dr Jarkko RAUTIO University of Eastern Finland - Finnish Pharmaceutical Society, Finland Dr Antoni TORRENS Esteve, Spain - EFMC Executive Committee Dr Matthew TOZER Consultant, United Kingdom - EFMC Executive Committee Prof. Dr Serge VAN CALENBERGH Ghent University - Medicinal and Bioorganic Chemistry Division of Royal Flemish Chemical Society (KVCV), Belgium Dr Luc VAN HIJFTE Mercachem-Syncom - EFMC Executive Committee Dr Franz VON NUSSBAUM Bayer Pharma AG - Division of Medicinal Chemistry of the German Chemical Society (GDCh), Germany Dr Eylon YAVIN The Hebrew University of Jerusalem - The Medicinal Chemistry Section of the Israel Chemical Society, Israel

[close]

p. 13

AB Advisory Board 9 EFMC YEARBOOK 2019 The Advisory Board is an EFMC consulting body for the Executive Committee assisting in assessing the Federation’s strategic goals. The tasks of the AB consist of: • advising on EFMC policy related matters internally and externally • proposing novel scientific or political initiatives to the Executive Committee • proposing strategies on how to increase awareness of Medicinal Chemistry and support of the community in Europe • proposing strategies on how to affect and interact with stakeholders in Europe The Advisory Board is composed of eminent scientists in life sciences and medicinal chemistry and is chaired by the Past President. Current Board Membership: • Koen AUGUSTYNS – AB Chair University of Antwerp, Belgium • Maria Laura BOLOGNESI University of Bologna, Italy • Karin BRINER Novartis, USA • François DIEDERICH ETH Zürich, Switzerland • Anette GRAVEN SAMS Lundbeck, Denmark • Herbert WALDMANN Max Planck Institute of Molecular Physiology, Germany • Tony WOOD GlaxoSmithKline, United Kingdom

[close]

p. 14

WG Groups 10 Influence on European Science Policy Soon after its creation, the working group started a collaboration with EuChemS to be involved in information activities and increase the visibility of EFMC within European institutions. The aim of the working group is to increase awareness of the importance of Medicinal Chemistry to address global health problems, as well as to position the EFMC as an expert organisation in its discipline. The partnership with EuChemS initially took the form of a workshop organised at the EU Parliament on “Solving Antimicrobial Resistance”, together with The Science & Technology Options Assessment (STOA), an official organ of the European Parliament responsible for technology assessment. Its task is to carry out expert, independent assessments of the impact of new technologies and identify long-term, strategic policy options. A recent workshop was held on November 2018 with EuChemS, and chaired by Member of the European Parliament Pavel Poc. The workshop looked at the causes and treatment options for Parkinson’s disease, as well as at patient needs, medicinal chemistry, animal models and clinical research requirements. Funding directions for the Horizon Europe research framework programme were included in the discussion. A recent achievement of the working group was to have Medicinal Chemistry included in the panel structure of the European Research Council, to ensure better evaluation of medicinal chemistry-based projects and better access to ERC grants. Influencing and guiding European Science Policy requires time and effort. By becoming one of its supporting members, EFMC became more closely associated with EuChemS, and will continue its efforts to give medicinal chemistry a voice in the European Parliament. Current membership: • Anders Karlén (Chair), Uppsala University, Sweden • Uli Stilz, Novo Nordisk, Denmark • Rob Leurs, VU University Amsterdam, The Netherlands • Christophe Genicot, UCB Biopharma, Belgium • Danijel Kikelj, University of Ljubljana, Slovenia • Phil Jones, European Screening Centre Newhouse, University of Dundee, United Kingdom

[close]

p. 15

Chemical Biology 11 EFMC YEARBOOK 2019 EFMC aims to advance the science of medicinal chemistry and chemical biology, which it sees as a continuum. The objective of the working group is therefore to ensure that all members of this extended scientific community are adequately represented in the activities of EFMC, and to develop chemical biology-related activities. In practice, EFMC events already include chemical biology, for instance as a dedicated stream in the program of the International Symposium on Medicinal Chemistry (EFMCISMC), but more can be done. For instance, actions such as the rebranding of the “Nauta Pharmacochemistry Award for Medicinal Chemistry and Chemical Biology” have been implemented, more clearly indicating its inclusion of chemical biology. EFMC and the International Chemical Biology Society (ICBS) have recently signed an agreement to use the synergies resulting from their common scientific interests and complementary geographical coverage. Both societies will exchange sessions at their main meetings, information, and mutually support one another. In addition, EFMC has established good contacts with the Life Science Division of EuChemS (LS EuChemS), and will be involved in the European Chemical Biology Symposium (EBCS)/LS EuChemS meeting in April 2019. EFMC looks forward to further strengthening the relationship with all its partners in chemical biology. Of note, a perspective article on “Joining Forces: The Chemical Biology–Medicinal Chemistry Continuum” illustrating how closely related both disciplines are, has been published by the members of the working group (Plowright et al. Cell Chem. Biol. 2017, 24(9), 1058-1065.) Current Membership: • Alleyn Plowright, Sanofi, Germany • Herbert Waldmann, Max Planck Institute of Molecular Physiology, Germany • Michelle Arkin, UCSF, USA • Christian Ottmann, Eindhoven University of Technology, The Netherlands • Yves P. Auberson, Novartis, Switzerland • Henk Timmerman, VU Amsterdam, The Netherlands

[close]

Comments

no comments yet